Side-by-side · Research reference

MatrixylvsPEG-MGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED9/39 cited

BAnimal-MechanisticHUMAN-REVIEWED2/69 cited

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

01Mechanism of Action

Parameter

Matrixyl

PEG-MGF

Primary target

Dermal fibroblastsPaccola 2025

IGF-1 receptor on muscle satellite cells and myocytes

Pathway

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Downstream effect

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Feedback intact?

—

Partially bypassed — does not require hepatic IGF-1 synthesis

Origin

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Antibody development

—

Unknown — no long-term human immunogenicity data

02Dosage Protocols

Parameter

Matrixyl

PEG-MGF

Formulation concentration

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

—

Application frequency

Twice daily (AM/PM)

Standard cosmeceutical protocol.

—

Duration

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

—

In vitro evidence

Fibroblast viability + ECM gene upregulationPaccola 2025

—

Vehicle

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

—

Research dose range

—

100–200 mcg

Extrapolated from animal models; no validated human protocols.

Frequency

—

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

Half-life

—

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

Evidence basis

—

Animal / mechanistic

Reconstitution

—

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

PEG molecular weight

—

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

Timing

—

Within 30–60 min post-training

Aligns with endogenous MGF window.

03Metabolic / Fat Loss Evidence

Parameter

Matrixyl

PEG-MGF

Primary target

—

Muscle tissue (satellite cells, myocytes) — not adipose-specific

Indirect metabolic effect

—

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

Body composition

—

Lean mass preservation / hypertrophy focus

Fat loss evidence

—

No direct human or animal RCT data for PEG-MGF-driven fat reduction

04Side Effects & Safety

Parameter

Matrixyl

PEG-MGF

Irritation

Mild erythema, pruritus in sensitive skin (rare)

—

Allergic reaction

Contact dermatitis (uncommon)

—

Systemic absorption

Negligible — topical application only

—

Injection site reaction

—

Erythema, induration (common with SQ peptides)

Hypoglycemia risk

—

IGF-1 axis activation can lower blood glucose

IGF-1R overstimulation

—

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

Fluid retention

—

Possible with IGF-1 pathway activation (dose-dependent)

PEG accumulation

—

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

Antibody formation

—

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

Cancer risk

—

IGF-1 axis stimulation contraindicated in active malignancy

Human safety data

—

Absent — no published human trials for PEG-MGF

Absolute Contraindications

Matrixyl

·Known hypersensitivity to palmitoyl peptides

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Relative Contraindications

Matrixyl

·Active dermatitis or open wounds at application site

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

05Administration Protocol

Parameter

Matrixyl

PEG-MGF

1. Cleanse

Wash face with gentle cleanser. Pat dry.

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

2. Application

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

3. Timing

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

4. Storage

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

5. Needle

—

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

06Stack Synergy

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair